SOURCE: Masimo


April 30, 2014 16:05 ET

Masimo Reports First Quarter 2014 Financial Results

IRVINE, CA--(Marketwired - Apr 30, 2014) - Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 29, 2014.

Q1 2014 Highlights (compared to Q1 2013):

  • Product revenue rose 3% to $132.2 million, net of a $2.6 million current quarter adjustment to our deferred revenue estimate for a certain U.S. distributor; absent this adjustment, product revenue rose 5% to $134.8 million
  • Total revenue, including royalties, rose 3% to $139.8 million; absent the same $2.6 million adjustment, total revenue, including royalties, rose 5% to $142.4 million
  • Masimo rainbow revenue rose 23% to $12.9 million
  • SET® and rainbow® SET® unit shipments were 41,400 
  • Earnings per share rose 39% to $0.39 including a $0.09 gain related to an $8.0 million reversal of a prior period accrual

First quarter 2014 GAAP product revenues and total revenues, including royalties, were $132.2 million and $139.8 million, respectively, both increasing 3% over the prior year first quarter. Included within such revenues for the quarter was a $2.6 million adjustment related to a revision for deferred revenue related to inventory on-hand at one US distributor. Without this adjustment, first quarter 2014 product revenues rose 5% to $134.8 million, compared to $128.6 million for the first quarter of fiscal year 2013, and total revenue, including royalties, rose 5% to $142.4 million, up from $135.9 million for the first quarter of fiscal year 2013.

The company's worldwide direct product revenue in the first quarter of 2014 rose by 3%, or 5% without the adjustment, compared to the same period in 2013 and represented 84% of product revenue with and without the adjustment. OEM sales, which accounted for 16% of product revenue, rose by 2% compared to the same period in 2013. Revenue from sales of Masimo rainbow products rose 23% to $12.9 million in the first quarter of 2014, compared to $10.5 million in the year-ago period. 

Net income for the first quarter of 2014 was $22.6 million, or $0.39 per diluted share, compared to net income of $16.4 million, or $0.28 per diluted share, in the first quarter of 2013. Net income for the first quarter of 2014 included the reversal of a Q4 2013 arbitration and related legal expense accrual in the amount of $8.0 million, or $0.09 per share.

During the first quarter of 2014, the company shipped approximately 41,400 SET® pulse oximetry and rainbow® Pulse CO-Oximetry™ units, excluding handheld units, an increase of 5% compared to the same prior-year period. Masimo estimates its worldwide installed base as of March 29, 2014 to be 1,231,000 units, up 10% from 1,117,000 units as of March 30, 2013. 

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, "Masimo began 2014 with continuing gains in market share and a 10% increase in our global installed base. In conjunction, with our 25th anniversary celebration, we plan to announce multiple new products in 2014, including innovative devices which will continue to help improve patient care and patient safety, while reducing cost of care. Our outlook remains positive as we drive towards our mission and financial objectives."

As of March 29, 2014, Masimo's cash and cash equivalents were $117.5 million, compared to $95.5 million as of December 28, 2013. The change reflects primarily net cash generated from operations.

2014 Financial Guidance
Masimo today is providing updated 2014 financial guidance. Masimo now expects fiscal 2014 total revenue to be approximately $588 million to $598 million, including product revenue of approximately $560 million to $570 million and royalty revenue of approximately $28 million. In addition, Masimo now expects fiscal 2014 GAAP earnings per share to range between $1.24 and $1.33. Each of the components of Masimo's guidance set forth above is an estimate only and actual performance could differ. 

Conference Call
Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. A live webcast of the call will be available online from the investor relations page of the company's website at The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 31415337. After the live webcast, the call will be available on Masimo's website through May 30, 2014. In addition, a telephonic replay of the call will be available through May 14, 2014. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 31415337.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at

Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our expectations for full fiscal year 2014 total, product, rainbow and royalty revenues and GAAP earnings per share; our plan to announce multiple new products in 2014; our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies and reduce the cost of care; and demand for our technologies. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET® and Masimo rainbow® SET® products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; our ongoing litigation and related matters; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation

(unaudited) (in thousands)
    March 29,
  December 28,
Current assets                
  Cash and cash equivalents   $ 117,529     $ 95,466  
  Accounts receivable, net of allowance for doubtful accounts     74,065       76,759  
  Royalties receivable     7,500       7,300  
  Inventories     55,538       56,813  
  Prepaid expenses     10,437       9,243  
  Prepaid income taxes     908       3,740  
  Deferred tax assets     16,718       19,636  
  Other current assets     3,986       2,841  
    Total current assets     286,681       271,798  
Deferred cost of goods sold     64,401       61,714  
Property and equipment, net     25,486       24,866  
Intangible assets, net     28,169       28,104  
Goodwill     22,847       22,793  
Deferred tax assets     22,552       22,565  
Other assets     8,517       6,822  
    Total assets   $ 458,653     $ 438,662  
Current liabilities                
  Accounts payable   $ 33,685     $ 28,004  
  Accrued compensation     22,487       29,486  
  Accrued liabilities     16,448       23,028  
  Income taxes payable     2,533       2,406  
  Deferred revenue     21,680       20,755  
  Current portion of capital lease obligations     102       111  
      Total current liabilities     96,935       103,790  
Deferred revenue     569       566  
Capital lease obligations, less current portion     156       225  
Other liabilities     7,550       7,680  
      Total liabilities     105,210       112,261  
Commitments and contingencies                
  Masimo Corporation stockholders' equity:                
    Common stock     57       57  
    Treasury stock     (83,454 )     (83,454 )
    Additional paid-in capital     277,702       273,129  
    Accumulated other comprehensive income     4,014       3,995  
    Retained earnings     155,374       132,742  
      Total Masimo Corporation stockholders' equity     353,693       326,469  
  Noncontrolling interest     (250 )     (68 )
      Total equity     353,443       326,401  
      Total liabilities and equity   $ 458,653     $ 438,662  
(unaudited) (in thousands, except per share amounts)
    Three Months Ended
    March 29,
  March 30,
  Product   $ 132,232     $ 128,635  
  Royalty     7,582       7,307  
Total revenue     139,814       135,942  
Cost of goods sold     47,513       46,361  
Gross profit     92,301       89,581  
Operating expenses:                
  Selling, general and administrative     56,122       52,273  
  Research and development     13,996       14,167  
  Litigation award and defense costs     (8,010 )     --  
Total operating expenses     62,108       66,440  
Operating income     30,193       23,141  
Non-operating income (expense)     200       (2,326 )
Income before provision for income taxes     30,393       20,815  
Provision for income taxes     7,902       4,413  
Net income including noncontrolling interest     22,491       16,402  
Net loss attributable to the noncontrolling interest     141       26  
Net income attributable to Masimo Corporation stockholders     22,632     $ 16,428  
Net income per share attributable to Masimo Corporation stockholders:                
  Basic   $ 0.40     $ 0.29  
  Diluted   $ 0.39     $ 0.28  
Weighted average shares used in per share calculations:                
  Basic     56,705       57,240  
  Diluted     58,047       58,011  

The following table presents details of the share-based compensation expense that is included in each functional line item in the condensed consolidated statements of income (in thousands):

    March 29,
  March 30,
Cost of goods sold   $ 110   $ 101
Selling, general and administrative     2,088     2,610
Research and development     403     702
Total   $ 2,601   $ 3,413
(unaudited) (in thousands)
    Three Months Ended
    March 29,
  March 30,
Cash flows from operating activities:                
  Net income including noncontrolling interest   $ 22,491     $ 16,402  
  Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities:                
    Depreciation and amortization     3,043       2,783  
    Share-based compensation     2,601       3,413  
    Loss on disposal of property and equipment     2       78  
    Provision for doubtful accounts     232       142  
    Provision for deferred income taxes     2,926       --  
    Income tax benefit from exercise of stock options granted prior to January 1, 2006     24       12  
    Excess tax (benefit) deficit from share-based compensation arrangements     (31 )     164  
    Changes in operating assets and liabilities:                
      (Increase) decrease in accounts receivable     2,469       (72 )
      Increase in royalties receivable     (200 )     (70 )
      (Increase) decrease in inventories     1,288       (1,109 )
      Increase in deferred cost of goods sold     (2,687 )     (2,741 )
      Increase in prepaid expenses     (1,186 )     (425 )
      Decrease in prepaid income taxes     2,832       1,492  
      (Increase) decrease in other assets     (2,831 )     1,128  
      Increase in accounts payable     5,676       3,874  
      Decrease in accrued compensation     (6,996 )     (3,405 )
      Increase (decrease) in accrued liabilities     (6,587 )     341  
      Increase in income taxes payable     156       1,779  
      Increase in deferred revenue     929       1,102  
      Increase (decrease) in other liabilities     (130 )     213  
Net cash provided by operating activities     24,021       25,101  
Cash flows from investing activities:                
  Purchases of property and equipment     (2,840 )     (1,839 )
  Increase in intangible assets     (886 )     (1,107 )
Net cash used in investing activities     (3,726 )     (2,946 )
Cash flows from financing activities:                
  Repayments of capital lease obligations     (77 )     (84 )
  Proceeds from issuance of common stock     1,918       463  
  Excess tax benefit (deficit) from share-based compensation arrangements     31       (164 )
  Repurchases of common stock     --       (12,431 )
  Repurchases of equity by noncontrolling interest     (42 )     --  
Net cash provided by (used in) financing activities     1,830       (12,216 )
Effect of foreign currency exchange rates on cash     (62 )     82  
Net increase in cash and cash equivalents     22,063       10,021  
Cash and cash equivalents at beginning of period     95,466       71,554  
Cash and cash equivalents at end of period   $ 117,529     $ 81,575  

Contact Information